Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study.
Monteiro Spindola Marins L, Silva Torres T, Luz PM, Moreira RI, Leite IC, Hoagland B, Kallas EG, Madruga JV, Grinsztejn B, Veloso VG; PrEP Brasil Study Group. Monteiro Spindola Marins L, et al. Among authors: madruga jv. Int J STD AIDS. 2021 Nov;32(13):1231-1241. doi: 10.1177/09564624211031787. Epub 2021 Jul 26. Int J STD AIDS. 2021. PMID: 34311605
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
Aberg JA, Shepherd B, Wang M, Madruga JV, Mendo Urbina F, Katlama C, Schrader S, Eron JJ, Kumar PN, Sprinz E, Gartland M, Chabria S, Clark A, Pierce A, Lataillade M, Tenorio AR. Aberg JA, et al. Among authors: madruga jv. Infect Dis Ther. 2023 Sep;12(9):2321-2335. doi: 10.1007/s40121-023-00870-6. Epub 2023 Sep 26. Infect Dis Ther. 2023. PMID: 37751019 Free PMC article.
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B; DUET-1 study group. Madruga JV, et al. Lancet. 2007 Jul 7;370(9581):29-38. doi: 10.1016/S0140-6736(07)61047-2. Lancet. 2007. PMID: 17617270 Clinical Trial.
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B, De Castro N, Arnold V, Veloso VG, Morgado M, Pilotto JH, Brites C, Madruga JV, Barcellos NT, Santos BR, Vorsatz C, Fagard C, Santini-Oliveira M, Patey O, Delaugerre C, Chêne G, Molina JM; ANRS 12 180 Reflate TB study group. Grinsztejn B, et al. Among authors: madruga jv. Lancet Infect Dis. 2014 Jun;14(6):459-67. doi: 10.1016/S1473-3099(14)70711-X. Epub 2014 Apr 9. Lancet Infect Dis. 2014. PMID: 24726095 Clinical Trial.
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B; PrEP Brasil Study TeamClinical Trial Number 01989611. Hoagland B, et al. Among authors: madruga jv. J Int AIDS Soc. 2017 Apr 6;20(1):21472. doi: 10.7448/IAS.20.1.21472. J Int AIDS Soc. 2017. PMID: 28418232 Free PMC article.
Syndemics among individuals enrolled in the PrEP Brasil Study.
De Boni RB, Machado IK, De Vasconcellos MTL, Hoagland B, Kallas EG, Madruga JV, Fernandes NM, Cerqueira NB, Moreira RI, Goulart SP, Veloso VG, Grinsztejn B, Luz PM. De Boni RB, et al. Among authors: madruga jv. Drug Alcohol Depend. 2018 Apr 1;185:168-172. doi: 10.1016/j.drugalcdep.2017.12.016. Epub 2018 Feb 10. Drug Alcohol Depend. 2018. PMID: 29454927
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team. Grinsztejn B, et al. Among authors: madruga jv. Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18. Lancet HIV. 2018. PMID: 29467098 Clinical Trial.
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.
Tan DHS, Raboud JM, Szadkowski L, Grinsztejn B, Madruga JV, Figueroa MI, Cahn P, Barton SE, Clarke A, Fox J, Zubyk W, Walmsley SL; VALIDATE Study Group. Tan DHS, et al. Among authors: madruga jv. J Antimicrob Chemother. 2019 Feb 1;74(2):480-488. doi: 10.1093/jac/dky433. J Antimicrob Chemother. 2019. PMID: 30376108 Free PMC article. Clinical Trial.
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG. Marins LMS, et al. Among authors: madruga jv. PLoS One. 2019 Aug 20;14(8):e0221281. doi: 10.1371/journal.pone.0221281. eCollection 2019. PLoS One. 2019. PMID: 31430318 Free PMC article. Clinical Trial.
57 results